The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia

European Journal of Clinical Investigation
F C HagemenasD R Illingworth

Abstract

We have examined the influence of simvastatin, a competitive inhibitor of 3-hydroxy-3-methyl glutaryl coenzyme A reductase on plasma concentrations of lipids and lipoproteins, the rates of cholesterol biosynthesis and degradation of 125I-labelled LDL by freshly isolated mononuclear leucocytes and the 24 h urinary excretion of mevalonic acid in patients with heterozygous familial hypercholesterolaemia. Patients were treated with progressively increasing doses of simvastatin (20, 40, and 80 mg day-1) taken in a twice-daily dosage for a period of 6 weeks on each dose. Plasma concentrations of LDL cholesterol decreased by 36.6%, 45.6% and 47.1% respectively on the three doses. High-affinity degradation of 125I-LDL by freshly isolated mononuclear leucocytes increased significantly on the 20 mg day-1 dosage but no further increase was observed on doses of 40 and 80 mg of simvastatin per day. Rates of 2-14C acetate incorporation into cholesterol by freshly isolated mononuclear leucocytes (obtained 12-15 h after the last dose of simvastatin) increased by 62%, 71% and 29% in cells isolated from patients on 20, 40, and 80 mg day-1 of simvastatin compared with values at baseline. In contrast, the 24 h excretion of mevalonic acid in the ur...Continue Reading

References

May 1, 1989·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·F C Hagemenas, D R Illingworth
Apr 15, 1986·The American Journal of Cardiology·J M HoegD L Sprecher
Jun 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·C F ClarkeA M Fogelman
Feb 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·P T KovanenM S Brown
Sep 1, 1984·The Journal of Clinical Investigation·T S ParkerP J De Schepper
Dec 1, 1984·The Journal of Clinical Investigation·D R Illingworth, G J Sexton
Jul 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·D W BilheimerJ L Goldstein
Dec 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·E E Sundberg, D R Illingworth
Jul 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·A W AlbertsJ Springer
May 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·T S ParkerE H Ahrens
Jun 1, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D StåhlbergK Einarsson

❮ Previous
Next ❯

Citations

Oct 1, 1994·Clinical Cardiology·P T Kuo
Mar 1, 1991·British Journal of Clinical Pharmacology·I F McDowellD P Nicholls
Sep 1, 1992·Current Problems in Cardiology·J S Prihoda, D R Illingworth
Apr 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·M R SomaR Paoletti
Aug 1, 1997·Arteriosclerosis, Thrombosis, and Vascular Biology·A D MaraisJ Mountney
Aug 12, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Pedro MataJuan Badimón
Oct 5, 1992·The Medical Journal of Australia·L A SimonsA Parfitt
Nov 2, 1992·The Medical Journal of Australia·L A SimonsA Parfitt
Nov 18, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Hayato TadaMasakazu Yamagishi

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.